» Adjuvant Therapy in mRCC

This month Prof. Sandy Srinivas and Dr Roberto Iacovelli provide their thoughts and views on: Adjuvant Therapy in mRCC

Emerging treatments from multiple drug trials

Medical Oncologists, Prof. Sandy Srinivas and Dr Roberto Iacovelli, discuss the use of adjuvant therapy in metastatic renal cell carcinoma (mRCC). Discussion centres on drug trials, in particular, comparison of the ASSURE trial and the S-TRAC TRIAL. The ASSURE trial is a study of VEGF receptor tyrosine kinase inhibitors, sorafenib and sunitinib, and examines disease free survival as a primary endpoint. The S-TRAC trial is a study of the effect of sunitinib in treatment of clear-cell RCC, looking at disease free survival and overall survival. Our experts explore the differences between these two studies and cover details of other trials including the PROTECT trial of Pazopanib treatment in clear-cell RCC, and several other trials pertinent to adjuvant therapy in kidney cancer. Please explore the slides and watch the video to gain the latest clinical insights on adjuvant therapy in mRCC.

Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practised in this field now for more than 20 years. She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit. She serves as the Vice-chair on the National Comprehensive Cancer Center (NCCN) panel for prostate cancer and has co-authored numerous publications and book chapters. She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.